id,indexed_date,language,media_name,media_url,publish_date,title,url
ebd8a5b72128557b6b6a7b27576dd1462090943a0dc0aa93496b2c5f60037246,2025-10-24 12:18:49.875361+00:00,en,benzinga.com,benzinga.com,2025-10-24,Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference,https://www.benzinga.com/pressreleases/25/10/g48400498/denifanstat-achieved-all-endpoints-in-the-treatment-of-moderate-to-severe-acne-in-phase-3-clinical
1ba4d6025a6e9da794651260ec961c6b0a521272debbf70476e1dfedf8165d6b,2025-10-15 15:29:53.543862+00:00,en,benzinga.com,benzinga.com,2025-10-15,Beyond The Numbers: 10 Analysts Discuss Madrigal Pharmaceuticals Stock,https://www.benzinga.com/insights/analyst-ratings/25/10/48225153/beyond-the-numbers-10-analysts-discuss-madrigal-pharmaceuticals-stock
05a16e59857e634153424db55240f89a406c75513d98de3ae0854a4bf04fc9e2,2025-10-07 22:32:09.217231+00:00,en,benzinga.com,benzinga.com,2025-10-07,Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4),https://www.benzinga.com/pressreleases/25/10/g48087930/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4
1266c9530c204e1527de4db345275548c05075dd8a534a0ad8bb0f14b1f61e12,2025-10-07 12:22:07.071874+00:00,en,benzinga.com,benzinga.com,2025-10-07,Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025,https://www.benzinga.com/pressreleases/25/10/g48070533/sagimet-biosciences-announces-upcoming-presentation-at-aasld-the-liver-meeting-2025
556bc4e128b331446c2cc29f34eac7bcb10f5e414b8c8eb3dd005e1c841643e4,2025-10-01 14:28:49.709282+00:00,en,benzinga.com,benzinga.com,2025-10-01,Liver Health Supplements Market Outlook : Projected to Exceed USD 3.11 Billion by 2032 with a 12.8 % CAGR | Coherent Market Insights,https://www.benzinga.com/pressreleases/25/10/g47966994/liver-health-supplements-market-outlook-projected-to-exceed-usd-3-11-billion-by-2032-with-a-12-8-c
2dbce01792f4ab5c6a61c587c34013d20d731a7458a95694b3a6fb3dc8cb6bad,2025-09-30 01:21:53.588081+00:00,en,benzinga.com,benzinga.com,2025-09-29,A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 7 Analysts,https://www.benzinga.com/insights/analyst-ratings/25/09/47930455/a-glimpse-into-the-expert-outlook-on-madrigal-pharmaceuticals-through-7-analysts
4d7d2a0b7336cf5630070a1145432999676a62d82c4541456e2ef39edbd44924,2025-09-16 04:27:14.628983+00:00,en,forbes.com,forbes.com,2025-09-15,"NFL Legend Dan Marino Talks About His MASH, Liver Disease Diagnosis",https://www.forbes.com/sites/brucelee/2025/09/15/nfl-legend-dan-marino-talks-about-his-mash-liver-disease-diagnosis/
30bf0f91b738cf2f536987752062fb8425334bbc036165bac2209e89c682cd52,2025-09-12 15:20:30.894930+00:00,en,benzinga.com,benzinga.com,2025-09-12,A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 6 Analysts,https://www.benzinga.com/insights/analyst-ratings/25/09/47641330/a-glimpse-into-the-expert-outlook-on-madrigal-pharmaceuticals-through-6-analysts
d00cc6f2f4fe7fec0973930286ecdd67e3f89e3049f452fbbef72a02e02b2ba4,2025-09-10 11:38:41.977260+00:00,en,benzinga.com,benzinga.com,2025-09-10,Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit,https://www.benzinga.com/pressreleases/25/09/g47590570/sagimet-biosciences-announces-upcoming-presentations-at-9th-annual-mash-drug-development-summit
8aa7a3f598d122e33af48243af109c9a30b2402c73e251c1c4465ff3c36860f1,2025-08-28 15:28:23.340690+00:00,en,benzinga.com,benzinga.com,2025-08-28,"Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk's Wegovy in MASH, According to Spherix Global Insights",https://www.benzinga.com/pressreleases/25/08/g47387534/despite-early-low-awareness-physicians-forecast-swift-adoption-of-novo-nordisks-wegovy-in-mash-acc
deac9148cb10449436e18c08d970a50fc693ba7a0432e59c4064b6df2d040628,2025-08-28 13:24:55.899224+00:00,en,investors.com,investors.com,2025-08-28,Can Novo And Its Linchpin Drug Make A Comeback?,https://www.investors.com/news/technology/novo-nordisk-stock-wegovy-approval-mash-rezdiffra-madrigal-pharmaceuticals/
75872faccf09a31b3c3e85bf711d393af6bf68ce22f7cdee9ddfd63e7099560e,2025-08-26 19:32:46.726190+00:00,en,benzinga.com,benzinga.com,2025-08-26,Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker,https://www.benzinga.com/analyst-stock-ratings/initiation/25/08/47342596/gyre-therapeutics-gains-attention-as-under-the-radar-liver-fibrosis-drug-maker
6eb11a571c7e2b62a22e40200a9283d7a9ce9bf9fbeb74db3c27ad583b74f10c,2025-08-20 08:21:20.192694+00:00,en,benzinga.com,benzinga.com,2025-08-19,Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis,https://www.benzinga.com/pressreleases/25/08/g47220728/madrigal-receives-european-commission-approval-for-rezdiffra-resmetirom-for-the-treatment-of-mash-
b5bb46eab96c551ec20757199ad8456ded74e038549c212fb479458c3c0ecec5,2025-08-18 16:22:14.836340+00:00,en,investors.com,investors.com,2025-08-18,Novo Pops As A New Wegovy Approval Slams A Key Rival,https://www.investors.com/news/technology/novo-nordisk-stock-wegovy-mash-approval-madrigal-pharmaceuticals-rezdiffra/
03c1939e2d4ccc68a3462dbbbf3fae79f258346c1a7fdf8c5b1f31ab7b41f58d,2025-08-18 11:27:32.710762+00:00,en,benzinga.com,benzinga.com,2025-08-18,What's Going On With Novo Nordisk Stock Monday? - Novo Nordisk (NYSE:NVO),https://www.benzinga.com/news/fda/25/08/47180869/novo-nordisks-wegovy-snags-conditional-fda-nod-for-fatty-liver-disease
840eb5589a6c48cd39dddf87d5af8a5b70c6a7ab3aeee52e81a4ceddac0a15e7,2025-08-18 10:23:18.174202+00:00,en,cnbc.com,cnbc.com,2025-08-18,Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease,https://www.cnbc.com/2025/08/18/novo-nordisk-shares-pop-5percent-after-wegovy-receives-us-approval-for-liver-disease.html
49c745d6d3d0107cf53fe3ba9b7cdc14b47f16adb5883ae10618c94a614576d2,2025-08-15 22:31:14.041207+00:00,en,reuters.com,reuters.com,2025-08-15,Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH,https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-wegovy-gets-accelerated-us-approval-liver-disease-mash-2025-08-15/
cd5a79cd89b8f7cb9f7826ff1845a06a19f5a5cce6883f973e82bcc022e2866d,2025-08-08 06:23:42.508928+00:00,en,benzinga.com,benzinga.com,2025-08-07,Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4),https://www.benzinga.com/pressreleases/25/08/g46979086/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4
0024587b3391b18d48c02fce267cdc7ea9bf362e4fb1ee7e6b38dbd17125730b,2025-08-05 12:18:06.897347+00:00,en,benzinga.com,benzinga.com,2025-08-05,Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates,https://www.benzinga.com/pressreleases/25/08/g46852496/madrigal-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-corporate-upda
1bdec8544b6623f89ae95859d394e338d026b02a162629c3c7b5085fbd5e04c9,2025-07-30 10:20:43.059566+00:00,en,reuters.com,reuters.com,2025-07-30,Madrigal signs up to $2 billion deal to develop CSPC Pharma's GLP-1 drug,https://www.reuters.com/business/healthcare-pharmaceuticals/madrigal-signs-up-2-billion-deal-develop-cspc-pharmas-glp-1-drug-2025-07-30/
75dff7f47402013ed072880f510b249ebf756529b80f5dedfd10240b4674201a,2025-07-25 13:17:13.697124+00:00,en,benzinga.com,benzinga.com,2025-07-25,"Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025",https://www.benzinga.com/pressreleases/25/07/g46627672/madrigal-pharmaceuticals-to-release-second-quarter-2025-financial-results-and-host-webcast-on-augu
c1becaf2544578a9015054b16eeea39a7231426a55cf7ad5bc21c555950461b9,2025-07-22 21:34:10.523936+00:00,en,benzinga.com,benzinga.com,2025-07-22,Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH,https://www.benzinga.com/pressreleases/25/07/g46541040/madrigal-pharmaceuticals-secures-500-million-in-senior-secured-credit-from-blue-owl-managed-funds-
4220222b5a712af91f7c58bb482ab6889271613c06c355968345b06ceef584a0,2025-07-16 20:48:07.499957+00:00,en,benzinga.com,benzinga.com,2025-07-16,Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom),https://www.benzinga.com/pressreleases/25/07/g46439160/madrigal-pharmaceuticals-receives-notice-of-allowance-from-u-s-patent-and-trademark-office-for-new
98b13bbedb66823a407dc750d2c6d44dcdd9c55c225bbca7f7125118df62d3f7,2025-06-20 20:17:14.109161+00:00,en,benzinga.com,benzinga.com,2025-06-20,Madrigal's Fatty Liver Disease Drug Gets Recommendation - Madrigal Pharmaceuticals (NASDAQ:MDGL),https://www.benzinga.com/news/health-care/25/06/46035838/european-advisory-panel-backs-conditional-approval-for-madrigals-fatty-liver-disease-drug
ba21fe9eb16abbe0c581acd19b7cfa1104ffa295c794e15037d709dcfa01b3c7,2025-06-20 11:31:36.346241+00:00,en,reuters.com,reuters.com,2025-06-20,EU medicines regulator backs conditional authorisation for Madrigal's liver disease drug,https://www.reuters.com/business/healthcare-pharmaceuticals/eu-medicines-regulator-grants-conditional-authorisation-madrigals-liver-disease-2025-06-20/
8bb321cb4b1b40850013e4be89a8c9d6432f5022862cf0c7a626f67c3dd89a3a,2025-06-20 11:31:26.411746+00:00,en,benzinga.com,benzinga.com,2025-06-20,Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis,https://www.benzinga.com/pressreleases/25/06/g46021876/madrigal-receives-positive-chmp-opinion-for-resmetirom-rezdiffra-for-the-treatment-of-mash-with-mo
f768e7380fe5b5c7a9288f00101fe43bd76f056e050a5bbc0933efd51f30b5d7,2025-06-18 06:19:49.434866+00:00,en,benzinga.com,benzinga.com,2025-06-17,Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4),https://www.benzinga.com/pressreleases/25/06/g45984138/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4
fcc130e3d145998f403250be6edd6d252f5e78466d358ac0c28959e51fc3f3a0,2025-06-03 23:29:46.240122+00:00,en,oregonlive.com,oregonlive.com,2025-06-03,"Dear Doctor: What are some common causes, treatments, for reoccurring nosebleeds?",https://www.oregonlive.com/advice/2025/06/dear-doctor-what-are-some-common-causes-treatments-for-reoccurring-nosebleeds.html
b36cee1ad3b96c16e72f4b1ee3e15df9caaf527945309e9a276539f11a7c49bd,2025-06-03 16:31:18.127816+00:00,en,stltoday.com,stltoday.com,2025-06-03,"Dr. Roach: Milk thistle, though harmless, not recommended for MASLD",https://www.stltoday.com/life-entertainment/local/wellness/article_75bd7573-7692-4879-a35c-3622b5adaa9f.html
d70a96d09ad6754d3feffb8a9433018ae34b7f03eadd0d561d39d2d39d7a12ef,2025-06-02 12:35:03.075340+00:00,en,benzinga.com,benzinga.com,2025-06-02,Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference,https://www.benzinga.com/pressreleases/25/06/g45718755/madrigal-pharmaceuticals-to-participate-in-the-46th-annual-global-goldman-sachs-health-care-confer
ec253e07683ae6d381292fda14c31bdd87363a78aed7b675f91c90deb81b98cd,2025-05-22 12:37:06.447126+00:00,en,benzinga.com,benzinga.com,2025-05-22,"Sagimet Biosciences to Host Virtual KOL Event, ""Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)"" on May 29, 2025",https://www.benzinga.com/pressreleases/25/05/g45561952/sagimet-biosciences-to-host-virtual-kol-event-evaluating-the-synergistic-potential-of-a-combinatio
771f53807fa4cca0cd17cf96438c615ad7c11339559e0fdb3e0b6ca2f481cb13,2025-05-19 21:22:47.256587+00:00,en,benzinga.com,benzinga.com,2025-05-19,"Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions",https://www.benzinga.com/pressreleases/25/05/g45505305/aardvark-therapeutics-bolsters-leadership-team-with-strategic-hires-across-scientific-commercial-r
72ac2c1fda9b79883f08b5507e9528518d0ea5df71b9fe48c112a98324e5bd34,2025-05-13 23:23:25.304642+00:00,en,benzinga.com,benzinga.com,2025-05-13,Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Treatment Options,https://www.benzinga.com/pressreleases/25/05/n45393723/liver-fibrosis-market-to-witness-rapid-growth-at-a-cagr-of-24-during-the-forecast-period-2025-2034
1a797803e3981c1a11736e483fa7ff20ab1fbb0b8186da29bbc2c8bad3e36fad,2025-05-10 12:29:56.455813+00:00,en,benzinga.com,benzinga.com,2025-05-10,Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis,https://www.benzinga.com/pressreleases/25/05/g45335059/madrigal-announces-new-clinical-data-demonstrating-rezdiffra-resmetirom-significantly-improved-mul
36641c93c98f6c340cedbc041c9e88fd70f3581d681e546098d76e6da2207f71,2025-05-01 19:25:53.049065+00:00,en,abcnews.go.com,abcnews.go.com,2025-04-30,Active ingredient in weight loss drug Wegovy may help treat type of fatty liver disease: Study,https://abcnews.go.com/Health/active-ingredient-weight-loss-drug-wegovy-treat-type/story?id=121312107
660d1b6226e87d3e2c157c15f7e9b4e410372d5b7421a0819251dd70f841ea20,2025-05-01 19:17:37.426745+00:00,en,upi.com,upi.com,2025-05-01,Ozempic for fatty liver disease: What to know about the new findings,https://www.upi.com/Health_News/2025/05/01/ozempic-fatty-liver/7821746100465/
b5dedca5d64f7494959dcb8a0047e8dfc0c0b941d715e1e025d8594d19d9a35a,2025-05-01 02:24:37.092218+00:00,en,seattletimes.com,seattletimes.com,2025-04-30,"Wegovy can treat a dangerous liver disease, study finds",https://www.seattletimes.com/seattle-news/health/wegovy-can-treat-a-dangerous-liver-disease-study-finds/?utm_source=RSS&utm_medium=Referral&utm_campaign=RSS_all
d8e1d87382aa81f5578b4a78e6258f91cbdfe97d9a2805ba9191236e9abb61dd,2025-04-30 22:26:54.905590+00:00,en,nbcnews.com,nbcnews.com,2025-04-30,Wegovy treated a serious form of liver disease in a major clinical trial,https://www.nbcnews.com/health/health-news/wegovy-treated-serious-form-liver-disease-major-clinical-trial-rcna203677
0b55e36d94ac9f1ce73d8aa8ea3cde20bc71a6d9499149356fffe9e290b3e0cf,2025-04-30 22:18:21.891536+00:00,en,gizmodo.com,gizmodo.com,2025-04-30,Semaglutide Shows Major Promise for Treating Serious Liver Disease,https://gizmodo.com/semaglutide-shows-major-promise-for-treating-serious-liver-disease-2000596492
d0b6733395da013fb9841d3782b6294c237d0813c6b6d963d5d3d3ae848a61cb,2025-04-18 13:19:03.167430+00:00,en,benzinga.com,benzinga.com,2025-04-18,"Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025",https://www.benzinga.com/pressreleases/25/04/g44883117/madrigal-pharmaceuticals-to-release-first-quarter-2025-financial-results-and-host-webcast-on-may-1
83dc1760c40e85378f16b761b9e50fc83a6491d069ba974f41c70b24766ad26c,2025-03-20 16:38:11.307406+00:00,en,benzinga.com,benzinga.com,2025-03-20,"Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy",https://www.benzinga.com/pressreleases/25/03/n44415906/galmed-pharmaceuticals-secures-new-patent-grant-extending-aramchols-patent-protection-to-2039-stre
e08ef23e7a0258f48dc45bebb0f34f4a113c6c948e2c16a802689cdc9a63d058,2025-03-12 10:20:12.079101+00:00,en,benzinga.com,benzinga.com,2025-03-11,"Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors",https://www.benzinga.com/pressreleases/25/03/g44243978/madrigal-appoints-jacqualyn-a-fouse-ph-d-to-its-board-of-directors
dc2a6b9952e230983d300ef73ca6e49381882ecfa6b5c6342e7c2665c00d6f8a,2025-02-26 18:21:17.066715+00:00,en,benzinga.com,benzinga.com,2025-02-26,Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis,https://www.benzinga.com/general/biotech/25/02/43981624/madrigal-pharmaceuticals-stock-jumps-on-new-two-year-data-showing-potential-benefit-of-rezdiffra-
dd1721184613a0a2f096f700858ce4926829176751ba9f8aa807ec3c9b0de7e8,2025-01-10 12:29:16.927921+00:00,en,sun-sentinel.com,sun-sentinel.com,2025-01-10,Is ‘Dry January’ the time to focus on your liver health?,https://www.sun-sentinel.com/2025/01/10/is-dry-january-the-time-to-focus-on-your-liver-health/
0d695df03e99c35b5edfc7d6e9572cba71118bfe0a514c02b598b9a84b8cab37,2025-01-08 17:54:49.631932+00:00,en,cnbc.com,cnbc.com,2025-01-08,Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market,https://www.cnbc.com/2025/01/08/healthy-returns-fda-approvals-fall-in-2024-transcarent-acquires-accolade.html
e95a933c873d0c84e483847aff02a567be01efd431d211a9f1c2b810a8407307,2025-01-03 13:29:37.981313+00:00,en,benzinga.com,benzinga.com,2025-01-03,Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference,https://www.benzinga.com/pressreleases/25/01/g42783587/madrigal-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference
10f9b0bb5cbfdff890f1af27939f223691a81a4deec8d291cfc3f907f2735d72,2024-11-26 11:38:41.532333+00:00,en,benzinga.com,benzinga.com,2024-11-25,Top 3 Health Care Stocks That May Dip This Month,https://www.benzinga.com/24/11/42162699/top-3-health-care-stocks-that-may-dip-this-month
1994d2ba72e0e3d6cf6b9af574e03dcf95c457b4e63fc48402b536504b4c13d8,2024-11-13 22:17:27.490976+00:00,en,benzinga.com,benzinga.com,2024-11-13,GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024,https://www.benzinga.com/pressreleases/24/11/g41954316/genfit-announces-corporate-updates-and-upcoming-participation-at-the-liver-meeting-2024
e5ec1ff555362dffc820b558fd8db6b666f5cfea54c9ac0a725d1a3b8516d33b,2024-11-02 01:18:25.508286+00:00,en,investors.com,investors.com,2024-11-01,Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets.,https://www.investors.com/news/technology/madrigal-stock-novo-nordisk-mash-treatment-rezdiffra/?src=A00220&yptr=yahoo
1e5ca3b55d8ae74e28aabf3d3561890645436e7022bbb48ee14783fc839aaf46,2024-11-01 19:22:33.801656+00:00,en,investors.com,investors.com,2024-11-01,Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets.,https://www.investors.com/news/technology/madrigal-stock-novo-nordisk-mash-treatment-rezdiffra/
a06217516d32dbe3ec6cae6c1c304021336954c19e6a5a73ed0424aecd1aa302,2024-10-30 13:23:01.213679+00:00,en,benzinga.com,benzinga.com,2024-10-30,"CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories",https://www.benzinga.com/pressreleases/24/10/g41623342/cytodyn-appoints-dr-melissa-palmer-m-d-as-lead-consultant-in-hepatology-announces-follow-up-inflam
c4eb41de309504d3ab9864eb91c29e00da83d788d02b39fcce57bdf0f5847ada,2024-10-30 12:40:05.120449+00:00,en,benzinga.com,benzinga.com,2024-10-30,Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®,https://www.benzinga.com/pressreleases/24/10/g41622421/madrigal-pharmaceuticals-to-present-multiple-rezdiffra-resmetirom-abstracts-in-nashmash-at-the-aas
c4c8b39c4e929e8157168f77f523ea22e20eefc8cfef8f23c59109b9fa1d1b7f,2024-10-18 13:18:30.939288+00:00,en,benzinga.com,benzinga.com,2024-10-18,"Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024",https://www.benzinga.com/pressreleases/24/10/g41400129/madrigal-pharmaceuticals-to-release-third-quarter-2024-financial-results-and-host-webcast-on-octob
ad8e9631d48531574e06c0f61bbc48e2f9ecaf8fbceee0b778964f4fdc100bf0,2024-10-17 14:26:13.582023+00:00,pt,theconversation.com,theconversation.com,2024-10-17,Esteatose hepática: como e por quê o acúmulo de gordura no fígado se tornou uma epidemia global e preocupante,https://theconversation.com/esteatose-hepatica-como-e-por-que-o-acumulo-de-gordura-no-figado-se-tornou-uma-epidemia-global-e-preocupante-240780
d635e91ea636770728539a8f9bc518baf023295294dd527496fb6a68abfbfeaa,2024-09-24 23:19:48.261809+00:00,en,benzinga.com,benzinga.com,2024-09-24,CytoDyn Announces Preliminary Findings in Study with SMC Laboratories,https://www.benzinga.com/pressreleases/24/09/g41000848/cytodyn-announces-preliminary-findings-in-study-with-smc-laboratories
d5aabba316fac6fc741b9a6cc26d491202ebcf69b40901d37c0900a4ef5a0079,2024-08-31 10:39:01.068096+00:00,en,dailydot.com,dailydot.com,2024-08-31,‘20% of people in the U.S. have fatty liver disease’: Doctor reveals the most common sign of fatty liver disease. Here’s what to know,https://www.dailydot.com/news/most-common-signs-of-fatty-liver-disease/
e39e7957dbef6a39d6447b16fd34e19631045848b2db53c3bc19097ca505762d,2024-08-26 12:30:24.750920+00:00,en,benzinga.com,benzinga.com,2024-08-26,"Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference",https://www.benzinga.com/pressreleases/24/08/g40549840/madrigal-pharmaceuticals-inc-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-co
6e8219e74d7a3b0925be7b489e12fcef6200bcd06dcd6ea357210c64748f3f1b,2024-08-23 21:18:28.838063+00:00,en,benzinga.com,benzinga.com,2024-08-23,Viking Rises 25% in a Month: Should You Buy or Wait?,https://www.benzinga.com/general/biotech/24/08/40531837/viking-rises-25-in-a-month-should-you-buy-or-wait
5daeb63e6d71e4d070b602cd2412a65df327dc2dec54321717ccdf187f71a666,2024-08-14 19:23:04.343810+00:00,en,benzinga.com,benzinga.com,2024-08-14,Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates,https://www.benzinga.com/pressreleases/24/08/g40363913/sagimet-biosciences-reports-second-quarter-2024-financial-results-and-provides-corporate-updates
1077a10ba50f8f201a5e10903e9f7b1e3ecd9386639b6a78815971c86706d549,2024-08-02 18:19:51.467996+00:00,en,benzinga.com,benzinga.com,2024-08-02,Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel,https://www.benzinga.com/pressreleases/24/08/g40126933/madrigal-pharmaceuticals-appoints-shannon-kelley-as-general-counsel
dc742789b9ef63c4c098129005e50e6be48505ae6c28f7c8923df16225808bde,2024-07-24 23:17:11.238548+00:00,en,salon.com,salon.com,2024-07-24,Diabetes and obesity can damage the liver to the point of failure,https://www.salon.com/2024/07/24/diabetes-and-obesity-can-damage-the-liver-to-the-point-of-failure--but-few-people-know-their-risk_partner/
7d66cce7d65d9af500f44630a9543d19b1afed89372dafbe9778d6a46a08ec22,2024-07-24 01:23:30.140821+00:00,en,upi.com,upi.com,2024-07-23,Few people with diabetes understand their risk of liver disease,https://www.upi.com/Health_News/2024/07/23/few-people-diabetes-understand-risk-liver-disease/8671721657111/
f6fe37ed8b78a1c919704f2e9462b02c252f27aa57f89526c3bd19e84bfc94f0,2024-07-23 10:33:32.551200+00:00,en,rawstory.com,rawstory.com,2024-07-23,Diabetes and obesity can damage the liver to the point of failure,https://www.rawstory.com/diabetes-and-obesity-can-damage-the-liver-to-the-point-of-failure/
9ff987060c8dc682c01e86a25f1dac8bdbcf32a7feb57642018912bc7447215b,2024-07-22 14:21:13.438233+00:00,en,theconversation.com,theconversation.com,2024-07-22,Diabetes and obesity can damage the liver to the point of failure – but few people know their risk of developing liver disease,https://theconversation.com/diabetes-and-obesity-can-damage-the-liver-to-the-point-of-failure-but-few-people-know-their-risk-of-developing-liver-disease-231442
5cd50234519c2c33fb4fd9229bdfd3d38b4490584cb07dc6b608c66800fb8b22,2024-06-26 21:22:11.634917+00:00,en,benzinga.com,benzinga.com,2024-06-26,Specialists in Gastroenterology and GI Alliance Begin Prescribing Groundbreaking Rezdiffra for Fatty Liver Disease,https://www.benzinga.com/pressreleases/24/06/g39500309/specialists-in-gastroenterology-and-gi-alliance-begin-prescribing-groundbreaking-rezdiffra-for-fat
ff4b984aa3d3d891e923fa3dbae663b4a84f50fc832b4cea15a60d2df3757b71,2024-06-17 21:17:09.106597+00:00,en,benzinga.com,benzinga.com,2024-06-17,GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH,https://www.benzinga.com/pressreleases/24/06/g39365945/genfit-new-easl-easd-easo-clinical-practice-guidelines-for-masld-include-nis2-as-key-tool-for-dete
6b3883181b785d5cec6b2117340b382125593e6acb48e9d6a6c1b89373bc2452,2024-06-14 08:25:44.539762+00:00,en,benzinga.com,benzinga.com,2024-06-13,From Awareness to Action on Global Fatty Liver Day,https://www.benzinga.com/pressreleases/24/06/g39317551/from-awareness-to-action-on-global-fatty-liver-day
5b8801d8ba23a2496ec229b4a3781433da5cedddf5f3ebd4be3222eac6b48e48,2024-06-11 16:32:42.616323+00:00,en,benzinga.com,benzinga.com,2024-06-10,Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024,https://www.benzinga.com/pressreleases/24/06/n39262199/gannex-announces-poster-presentation-of-positive-interim-12-week-results-from-phase-ii-clinical-tr
d49bb7db600ca5e8fae4906f2c5e52c27bd08f238022abe983c42610a2b099ec,2024-06-06 12:31:08.477747+00:00,en,benzinga.com,benzinga.com,2024-06-06,Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress,https://www.benzinga.com/pressreleases/24/06/g39203429/madrigal-pharmaceuticals-announces-new-data-from-the-phase-3-maestro-nash-study-of-rezdiffra-resme
99883341384bfebfc984d5143a86e637fac33763c4c3e4c8c7023bb8d077bc38,2024-06-05 20:47:58.305401+00:00,en,benzinga.com,benzinga.com,2024-06-05,"What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?",https://www.benzinga.com/general/biotech/24/06/39192538/whats-going-on-with-fattly-liver-disease-focused-madrigal-pharmaceuticals-sagimet-biosciences-sha
b294d8789027f9a4cb58ba289e302d468a1a8c4e3f6319bc8db3b60493aa9bd4,2024-05-22 12:29:04.124365+00:00,en,benzinga.com,benzinga.com,2024-05-22,Anavex Life Sciences Announces Expansion of Leadership Team,https://www.benzinga.com/pressreleases/24/05/g38960624/anavex-life-sciences-announces-expansion-of-leadership-team
862f2e953207d02a9005f9d1e6c6f2759abc036ce0b8b4af0ecf74dbf8acb480,2024-05-08 06:33:29.104326+00:00,en,benzinga.com,benzinga.com,2024-05-07,Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates,https://www.benzinga.com/pressreleases/24/05/g38664131/madrigal-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corporate-updat
5f2788919ca82bd52a506ef8eac4700dc4dfec90319152033c6d2dd2ab77e098,2024-05-08 01:40:14.714367+00:00,en,benzinga.com,benzinga.com,2024-05-06,"Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Astellas Pharma",https://www.benzinga.com/pressreleases/24/05/g38649248/global-liver-disease-therapeutics-market-to-grow-rapidly-by-2030-examines-delveinsight-key-players
584a6d51007fc3680247f1c1e7374a650b02179600818f1460fa46f57608edc8,2024-04-10 00:33:27.046918+00:00,en,forbes.com,forbes.com,2024-04-08,Precision Diagnostics Can Save Money In Healthcare: What’s Holding Them Back?,https://www.forbes.com/sites/joshuacohen/2024/04/08/precision-diagnostics-can-save-money-in-healthcare-whats-holding-them-back/
36c040827145667563aad5dfed6373d89d4173f3569f2edfafebc7b265562b8e,2024-04-07 00:39:21.697209+00:00,en,benzinga.com,benzinga.com,2024-04-05,US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH),https://www.benzinga.com/pressreleases/24/04/g38109730/us-gastroenterologists-project-swift-uptake-of-madrigal-pharmaceuticals-rezdiffra-resmetirom-for-t
9b1020930a546bf858616869a4053f126ed760b235ac22880b8a0b88779367b4,2024-04-06 06:34:48.896773+00:00,en,benzinga.com,benzinga.com,2024-04-04,GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update,https://www.benzinga.com/pressreleases/24/04/g38100107/genfit-reports-full-year-2023-financial-results-and-provides-corporate-update
7609175e8cfdf667ceb809b03905b13f6ba7286c5b3d823377a566a8718ff256,2024-04-03 03:43:17.654966+00:00,en,investors.com,investors.com,2024-04-01,Biotech Stocks Are Tumbling — But The Top 5 Are Standouts,https://www.investors.com/news/technology/biotech-stocks-the-top-5-to-watch-amid-a-blazing-hot-run/?src=A00220&yptr=yahoo
e5f58d952103c64dbfe39bad227898460b9691ba41e524d9e2e3ed049ac1adcf,2024-03-31 01:00:27.257416+00:00,en,benzinga.com,benzinga.com,2024-03-29,Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update,https://www.benzinga.com/pressreleases/24/03/g38003674/galectin-therapeutics-reports-2023-financial-results-and-provides-business-update
ca2ae90840dc989577917693cc83db7881233758056233989e918c253c814a4c,2024-03-30 00:48:40.868143+00:00,en,rttnews.com,rttnews.com,2024-03-28,Biotech Stocks Facing FDA Decision In April 2024,https://www.rttnews.com/3435646/biotech-stocks-facing-fda-decision-in-april-2024.aspx
2a4e7d5a7203c1facc850eced0490c3e1368bbdb449f01077083cc65f81f7570,2024-03-23 00:49:40.373937+00:00,en,forbes.com,forbes.com,2024-03-21,InnovationRx: Google Is Developing An AI Health Coach For Fitbit,https://www.forbes.com/sites/katiejennings/2024/03/21/innovationrx-google-is-developing-an-ai-health-coach-for-fitbit/
96840bd4d0c9195fa0d5b213d4875c8267bb86ba9a75806e94927710733ce6af,2024-03-21 00:25:27.354234+00:00,en,benzinga.com,benzinga.com,2024-03-18,Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering,https://www.benzinga.com/pressreleases/24/03/g37811496/madrigal-pharmaceuticals-announces-pricing-of-upsized-600-million-public-offering
1b6fa70986da55615e50f499703124d2dff662178e538e859840d18330cb5dd2,2024-03-20 03:29:20.704150+00:00,en,benzinga.com,benzinga.com,2024-03-18,PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval,https://www.benzinga.com/pressreleases/24/03/g37797137/prism-marketview-spotlights-companies-leading-the-charge-in-liver-disease-treatment-following-land
e40281bd91a0aafa832f889fea967916c57450bf209507871ccf34f8ee2e3b6f,2024-03-20 03:27:25.276414+00:00,en,benzinga.com,benzinga.com,2024-03-18,Madrigal Pharmaceuticals Announces Proposed Public Offering,https://www.benzinga.com/pressreleases/24/03/g37799951/madrigal-pharmaceuticals-announces-proposed-public-offering
a9f707e17196208106100ea2be6a6031c2353762c0602cba3eb6d0f96cdc0e17,2024-03-20 02:49:16.205821+00:00,en,cleveland.com,cleveland.com,2024-03-18,"When diet and exercise aren’t enough, new drug can treat fatty liver disease, says FDA",https://www.cleveland.com/news/2024/03/when-diet-and-exercise-arent-enough-new-drug-can-treat-fatty-liver-disease-says-fda.html
ed2d1e27913e69926a8d895f74b2996c67155a861a2f53c4e104e9c9f453b7ff,2024-03-19 05:53:40.884444+00:00,en,benzinga.com,benzinga.com,2024-03-17,A Groundbreaking Milestone in the Treatment of NASH and Liver Fibrosis,https://www.benzinga.com/pressreleases/24/03/g37768302/a-groundbreaking-milestone-in-the-treatment-of-nash-and-liver-fibrosis-anervea
fba86d43114effaf9bdc0923dc6a2a724621b5423ef006046c6798d12fc84ce2,2024-03-18 00:20:15.170494+00:00,ar,cnn.com,cnn.com,2024-03-16,أول دواء لعلاج التهاب الكبد الدهني غير الكحولي يحصل على موافقة بأمريكا,https://arabic.cnn.com/science-and-health/article/2024/03/16/rezdiffra-fda-nash
efcd694f601f4c5b0f5dad604c34df288d99f6407d4017ded32d5e3d71b7bfc1,2024-03-17 11:51:01.919036+00:00,en,ibtimes.com,ibtimes.com,2024-03-15,US Approves First Drug For Severe Form Of Fatty Liver Disease,https://www.ibtimes.com/us-approves-first-drug-severe-form-fatty-liver-disease-3727268
d9e216721a0f69dd9a65d77d480bb94e9cbf44aba85e4d1e576bc1f7f5940d3b,2024-03-17 08:23:55.618235+00:00,en,rttnews.com,rttnews.com,2024-03-15,"Galmed Granted European Patent For Use Of Aramchol-Resmetirom To Treat NASH/MASH, Liver Fibrosis",https://www.rttnews.com/3432614/galmed-granted-european-patent-for-use-of-aramchol-resmetirom-to-treat-nash-mash-liver-fibrosis.aspx
dfeab038b1b71a7ab3b7a939b23197a00b8e7d681d257b703ed6e3fb0bb54e98,2024-03-17 06:10:04.702787+00:00,en,benzinga.com,benzinga.com,2024-03-15,"Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday’s Mid-Day Session - Adobe (NASDAQ:ADBE), AdTheorent Holding (NASDAQ:ADTH)",https://www.benzinga.com/news/24/03/37756640/why-jabil-shares-are-trading-lower-by-over-14-here-are-other-stocks-moving-in-fridays-mid-day-sessio
4c204feb55a7a9feaf4203ab15adf040ef3e5ba80f254239de4ed45094cacb9a,2024-03-17 06:09:16.949043+00:00,en,benzinga.com,benzinga.com,2024-03-15,"Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis",https://www.benzinga.com/pressreleases/24/03/n37744419/galmed-announces-grant-of-new-patent-for-the-combination-of-aramchol-with-resmetirom-mgl-3196-rezd
929be041cdd6cf3dead6e17d418612a777b43efd79830450e0fa4d0af5a7fad7,2024-03-17 06:08:56.228832+00:00,en,benzinga.com,benzinga.com,2024-03-15,Why Is Madrigal Pharmaceuticals Stock Trading Higher On Friday? - Madrigal Pharmaceuticals (NASDAQ:MDGL),https://www.benzinga.com/general/biotech/24/03/37751655/fda-conditionally-approves-madrigal-pharmaceuticals-resmetirom-as-first-treatment-for-fatty-liver
7213a0a2d4346ba8f37ee2c464c675e689d98f5acb4852c8ccb72bed3ea2596e,2024-03-17 06:08:54.908927+00:00,en,benzinga.com,benzinga.com,2024-03-15,"FDA Approves Intuitive Surgical's Da Vinci 5 Surgical System, Analyst Outlines Sees Long-Term Growth Potential",https://www.benzinga.com/government/24/03/37751869/fda-approves-intuitive-surgicals-da-vinci-5-surgical-system-analyst-outlines-sees-long-term-growth-p
56ce510ff48aa5e8cdebb890a3303053b33b01d5377ab9c29aaa561b2de02b06,2024-03-17 06:07:57.295978+00:00,en,benzinga.com,benzinga.com,2024-03-15,"Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday",https://www.benzinga.com/news/24/03/37748602/blend-labs-reports-q4-results-joins-alta-equipment-despegar-com-and-other-big-stocks-moving-higher-o
0a78d6b0381fe0df51b701edc6bd10770d6c94766a2f401798e0c503c5c69ef0,2024-03-17 06:07:22.095715+00:00,en,benzinga.com,benzinga.com,2024-03-15,Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket,https://www.benzinga.com/news/24/03/37741520/why-cardlytics-shares-are-trading-higher-by-around-37-here-are-20-stocks-moving-premarket
f529a845478e67cc4a39dd2b75420dc84328ec2930b5cc18f4ec358db3417dc7,2024-03-17 05:22:47.990224+00:00,en,rawstory.com,rawstory.com,2024-03-15,U.S. approves first drug for severe form of fatty liver disease,https://www.rawstory.com/u-s-approves-first-for-severe-form-of-fatty-liver-disease/
d96b0a0f0d0ea40f01880e500a3989d7643140d4713f6406401d06c6f406372c,2024-03-17 04:08:32.206865+00:00,en,investors.com,investors.com,2024-03-15,"Nasdaq, S&P 500 Extend Losses As Adobe Casts Pall On Techs; Bitcoin Leader Reverses Higher",https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-adobe-stock/?src=A00220&yptr=yahoo
66c5b2edd84c7bc857de50990886c3f92ac89f771838a2ad364dacf474ddb027,2024-03-17 02:04:35.478576+00:00,en,upi.com,upi.com,2024-03-15,FDA approves Rezdiffra to treat liver disease,https://www.upi.com/Health_News/2024/03/15/FDA-liver-disease-drug/1301710508069/
8947dbbfc5c66abe9bccb5244ba84352c2ca3f9288b6725468abb4cd7987fe47,2024-03-16 02:07:19.518455+00:00,en,marketwatch.com,marketwatch.com,2024-03-14,Madrigal’s stock surges as FDA approves first drug for liver disease MASH,https://www.marketwatch.com/story/madrigal-pharmaceuticals-gets-first-fda-approval-for-drug-targeting-liver-disease-mash-bcadc9ea?g=433ddc90-75cd-492c-964f-ba73042458cc&mod=mw_rss_bulletins
a49526b1c8a2934d7d6f6ee114a848dc807095e1baf08ec05c775a826d25975e,2024-03-16 02:07:17.757214+00:00,en,marketwatch.com,marketwatch.com,2024-03-14,Madrigal’s stock surges as FDA approves first drug for liver disease MASH,https://www.marketwatch.com/story/madrigal-pharmaceuticals-gets-first-fda-approval-for-drug-targeting-liver-disease-mash-bcadc9ea?mod=mw_rss_topstories
2219bd2147302b41ecdfe887c1c430ef6be83a2ed23e6515bcb8684859c0556e,2024-03-16 00:49:04.640052+00:00,en,benzinga.com,benzinga.com,2024-03-14,FDA's Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population,https://www.benzinga.com/pressreleases/24/03/g37719675/fdas-approval-of-breakthrough-nash-treatment-opens-door-for-a-long-neglected-patient-population
0c098518f727a35d0e7d56c257f7c7fa58748efcdd25672aaa27eefd68c13891,2024-03-16 00:48:11.248249+00:00,en,benzinga.com,benzinga.com,2024-03-14,Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis,https://www.benzinga.com/pressreleases/24/03/g37717139/madrigal-pharmaceuticals-announces-fda-approval-of-rezdiffra-resmetirom-for-the-treatment-of-patie
273cd7b67afcb0fe785670bd350b566602b765b4db52740f84015e30524ba0c5,2024-03-10 19:23:14.054485+00:00,en,benzinga.com,benzinga.com,2023-01-02,DelveInsight Evaluates a Robust Nonalcoholic Fatty Liver Disease Pipeline as 110+ Influential Pharma Players to Set Foot in the Domain,https://www.benzinga.com/pressreleases/23/01/g30250955/delveinsight-evaluates-a-robust-nonalcoholic-fatty-liver-disease-pipeline-as-110-influential-pharm
8ce901ddd319d64e1f33f229ff215ca9f04ff1b8f5250d120fea563f65ffe825,2024-03-10 18:24:53.979384+00:00,en,benzinga.com,benzinga.com,2023-01-03,5 Most Expensive Health Care Stocks You Should Worry About,https://www.benzinga.com/news/23/01/30255976/5-most-expensive-health-care-stocks-you-should-worry-about
9242e98d1680a088eadff58144f62650cee962d12fbe19efefca5f92f71486ac,2024-03-10 11:46:48.890029+00:00,en,benzinga.com,benzinga.com,2023-01-06,Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis,https://www.benzinga.com/pressreleases/23/01/g30308976/madrigal-announces-additional-positive-results-from-the-pivotal-phase-3-maestro-nash-clinical-tria
272f9f1d9eff3fcd2a8b5fda9f9a40784ea75c652164c53693a863888645c89e,2024-03-08 18:55:28.698334+00:00,en,benzinga.com,benzinga.com,2023-02-08,Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences,https://www.benzinga.com/pressreleases/23/02/g30807321/madrigal-pharmaceuticals-announces-participation-at-three-upcoming-investor-conferences
df90967b2070657aab4e9e344333d0532056fed98a34b6e9ca10161741314313,2024-03-08 11:06:24.346196+00:00,en,marketwatch.com,marketwatch.com,2023-02-13,Inside the NASH drug boom: New drugs for a ‘silent’ liver disease that affects millions near FDA approval,http://www.marketwatch.com/news/story.asp?guid=%7B20C06575-04D4-B545-7188-A9FD725ED321%7D&siteid=rss&rss=1
468c93cc3fdddd216ee2e216f60223688db03c3a7b697a2f8ce2f668c081b733,2024-03-07 20:57:39.332524+00:00,en,benzinga.com,benzinga.com,2023-02-23,Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results,https://www.benzinga.com/pressreleases/23/02/g31026017/madrigal-pharmaceuticals-provides-corporate-updates-and-reports-2022-fourth-quarter-and-full-year-
fb1ee8e9656c31149d15d160082f1182bd114f925a1f3a23c0860962cdee9cdc,2024-03-01 00:39:36.425869+00:00,en,benzinga.com,benzinga.com,2024-02-28,Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results,https://www.benzinga.com/pressreleases/24/02/g37359286/madrigal-pharmaceuticals-provides-corporate-updates-and-reports-fourth-quarter-and-full-year-2023-
cabc3c3e80fec3f1c71b2f1cb9d30f34c1431b335bcb046ef333e3b8d5402855,2024-03-01 00:39:19.582251+00:00,en,benzinga.com,benzinga.com,2024-02-28,Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer,https://www.benzinga.com/pressreleases/24/02/g37359389/madrigal-pharmaceuticals-appoints-mardi-c-dier-as-chief-financial-officer
1c485829d2e850d74847d809fe6c5f51e4c656576b1711bb05ce9591882dd767,2024-02-29 17:43:35.999844+00:00,en,benzinga.com,benzinga.com,2023-04-18,Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial,https://www.benzinga.com/pressreleases/23/04/g31852658/madrigal-receives-breakthrough-therapy-designation-from-fda-for-resmetirom-and-completes-enrollmen
e382d51868b5a732e364f876bbdbe86eb9daffe1ff9463211b2ab530903cfb6a,2024-02-29 17:20:15.557838+00:00,en,benzinga.com,benzinga.com,2023-04-18,"Fatty Liver Diseases Treatment Market to Exhibit an Incredible Growth of USD 28 Billion by 2030, Size, Share, Trends, Key Drivers, Demand and Opportunity Analysis",https://www.benzinga.com/pressreleases/23/04/g31863387/fatty-liver-diseases-treatment-market-to-exhibit-an-incredible-growth-of-usd-28-billion-by-2030-si
4c40869aeda7bb1b4a74a0436416ea745c75ba50a86fb70fc0e6d829d41210d6,2024-02-29 04:19:04.542202+00:00,en,benzinga.com,benzinga.com,2023-04-27,"Hepatic Cirrhosis Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain - Madrigal, Zydus, Can-Fite BioPharma, Bristol-Myers Squibb, Boehringer Ingelheim, Grifols, Akero",https://www.benzinga.com/pressreleases/23/04/g32052975/hepatic-cirrhosis-market-evolving-at-a-rapid-pace-predicts-delveinsight-key-companies-active-in-th
253d72318d2e21581c75453ded3e97c8d07ba3b87a995c3be4703afce2130eb9,2024-02-29 02:43:57.803487+00:00,en,benzinga.com,benzinga.com,2023-04-28,PATIENT GROUPS DECLARE ICER REVIEW OF NASH MEDICATIONS CAUSES MORE UNCERTAINTY AND CONTROVERSIES THAN IT RESOLVES,https://www.benzinga.com/pressreleases/23/04/g32088286/patient-groups-declare-icer-review-of-nash-medications-causes-more-uncertainty-and-controversies-t
396f56be48ca24e69cee00e2c4ca08261a21eccb7de6e0fb76ab6b9d4501b98f,2024-02-28 23:01:32.730931+00:00,en,benzinga.com,benzinga.com,2023-05-01,ICER MIDWEST CEPAC WORKS TO KEEP UP WITH WELL-INFORMED NASH PATIENT ADVOCATES,https://www.benzinga.com/pressreleases/23/05/g32138248/icer-midwest-cepac-works-to-keep-up-with-well-informed-nash-patient-advocates
d80069987132e58fcde5e6769287012c198f735032ee856ed66377b6b867e353,2024-02-28 01:08:09.014181+00:00,en,benzinga.com,benzinga.com,2023-05-16,Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial,https://www.benzinga.com/general/biotech/23/05/32429316/viking-therapeutics-outperforms-expectations-analyst-increases-price-target-following-successful-
78d283b6ca89ec38ec0a830e2e6f77063a20f7e646ef1fc379bf05f32ef74638,2024-02-27 14:07:33.557484+00:00,en,benzinga.com,benzinga.com,2023-05-22,"The Rising NAFLD/NASH Epidemic Coupled with High Patient Need Offers Opportunities for Pharmaceutical Manufacturers to Capitalize Across Various Disease Stages, According to Spherix Global Insights",https://www.benzinga.com/pressreleases/23/05/n32521662/the-rising-nafldnash-epidemic-coupled-with-high-patient-need-offers-opportunities-for-pharmaceutic
e841f00d15c0449f63fcbbed2043a20a493d1a04520268245b26c6da6cb036ae,2024-02-27 12:59:03.084775+00:00,en,benzinga.com,benzinga.com,2023-05-23,Nonalcoholic Steatohepatitis Clinical Trial Pipeline Analysis of 100+ Companies | NASH Pipeline Report by DelveInsight,https://www.benzinga.com/pressreleases/23/05/g32536102/nonalcoholic-steatohepatitis-clinical-trial-pipeline-analysis-of-100-companies-nash-pipeline-repor
ce048b911a7837a3521318633b63c32e2f22c027ef1bdddfae328e445c490cc5,2024-02-27 00:50:49.516073+00:00,en,benzinga.com,benzinga.com,2023-06-01,Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences,https://www.benzinga.com/pressreleases/23/06/g32666772/madrigal-pharmaceuticals-announces-participation-at-two-upcoming-investor-conferences
b66f485a155fd939cddc8b4c9dce3a9f69d4f06f9249d2647865eb40110144e3,2024-02-26 17:52:57.083689+00:00,en,benzinga.com,benzinga.com,2023-06-06,Madrigal Pharmaceuticals Supports International NASH Day on June 8,https://www.benzinga.com/pressreleases/23/06/g32734523/madrigal-pharmaceuticals-supports-international-nash-day-on-june-8
382b3a008287ac75a6b17d409583f1761d37c17e428604e7515302309367af05,2024-02-25 20:30:56.324801+00:00,en,benzinga.com,benzinga.com,2023-06-22,Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™,https://www.benzinga.com/pressreleases/23/06/g32960175/madrigal-pharmaceuticals-presents-phase-3-maestro-nash-data-during-the-opening-general-session-of-
b219a52042202de6a5b669ecd46f44aa4778a6c906398043f9854633e5ccf931,2024-02-25 09:37:17.826722+00:00,en,benzinga.com,benzinga.com,2023-06-30,Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis,https://www.benzinga.com/pressreleases/23/06/g33076285/madrigal-pharmaceuticals-announces-rolling-submission-of-new-drug-application-to-u-s-fda-seeking-a
73a60cea32401c07a67f632cb1d87429087500bcb12c9423cec7653206e5e765,2024-02-25 09:19:13.409698+00:00,en,marketwatch.com,marketwatch.com,2023-06-30,Madrigal Pharmaceuticals’ stock up 5% as company starts rolling submission for FDA approval of NASH treatment,http://www.marketwatch.com/news/story/madrigal-pharmaceuticals-stock-up-5/story.aspx?guid=%7B20C06575%2D04D4%2DB545%2D7222%2D0E646E37B962%7D&siteid=rss
effa5735aae78c50c149e4fd37fe64b38303e3cf45d64bf36adc2724faa97d61,2024-02-25 08:39:33.938330+00:00,en,investors.com,investors.com,2023-06-30,Top 3% Biotech Pops; Can It Crack This Untapped $160 Billion Market?,https://www.investors.com/news/technology/mdgl-stock-rises-as-fda-mulls-its-nash-drug-on-the-heels-of-intercept-failure/
d3d4734f0960f937de958f3355c25e4c76a0f38203a023616257940bb07b0718,2024-02-24 18:39:49.216844+00:00,en,benzinga.com,benzinga.com,2023-07-12,"Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight",https://www.benzinga.com/pressreleases/23/07/n33207225/liver-cirrhosis-market-to-observe-impressive-growth-at-a-cagr-of-6-3-by-2032-predicts-delveinsight
3d703189a99ed93621b10e9fb5c358c53310843f8f8faa54e10e52401239d7f8,2024-02-24 13:26:04.060360+00:00,en,benzinga.com,benzinga.com,2023-07-17,Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis,https://www.benzinga.com/pressreleases/23/07/g33245986/madrigal-pharmaceuticals-completes-submission-of-new-drug-application-seeking-accelerated-approval
18a8d61a0756c35d16c4515c6fcbbd28b5408c2a2bea5a7167fa8e2a82abde22,2024-02-21 09:18:52.187756+00:00,en,benzinga.com,benzinga.com,2023-09-11,Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer,https://www.benzinga.com/pressreleases/23/09/g34434144/madrigal-pharmaceuticals-appoints-bill-sibold-as-chief-executive-officer
70db5432dfa6ddcddd7a9cf42cd9ae37940172f6741c4e39c351975c60fb617a,2024-02-21 06:24:59.532342+00:00,en,benzinga.com,benzinga.com,2023-09-13,Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis,https://www.benzinga.com/pressreleases/23/09/g34535787/madrigal-pharmaceuticals-announces-nda-acceptance-and-priority-review-of-the-new-drug-application-
e9e6e904025ee0b7d4340e752276ccc372bc0d2a188947d49cac12a37c750c5d,2024-02-21 04:28:52.821406+00:00,en,benzinga.com,benzinga.com,2023-09-14,Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),https://www.benzinga.com/pressreleases/23/09/g34594057/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4
f1e5541c276412cc725fea1ec03aab2583751526e6e8ffed573946bb783b1cbc,2024-02-20 07:35:28.416817+00:00,en,benzinga.com,benzinga.com,2023-09-28,Madrigal Pharmaceuticals Announces Proposed Public Offering,https://www.benzinga.com/pressreleases/23/09/g34986449/madrigal-pharmaceuticals-announces-proposed-public-offering
5bfb565fe3cc2d7cdcb03a14eb65b173b8f4c766cdfa40bb413db89f6b588985,2024-02-20 07:13:27.945936+00:00,en,bizjournals.com,bizjournals.com,2023-09-28,Montgomery County biopharma firm plans $500M stock offering while FDA reviews its NASH treatment application,https://www.bizjournals.com/philadelphia/news/2023/09/28/madrigal-pharmaceuticals-conshohocken-nash-stock.html?ana=RSS&s=article_search
12985f1c88c6b3d39bd022f0343eacdb72bb6db84b037cfbf9db739d916c5f91,2024-02-20 07:12:48.712740+00:00,en,benzinga.com,benzinga.com,2023-09-28,Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering,https://www.benzinga.com/pressreleases/23/09/g34990377/madrigal-pharmaceuticals-announces-pricing-of-500-million-public-offering
a2780d6db8ba149f6d6fbc48b7dd71897f7e3020e819e36f012084529e84b6d9,2024-02-20 07:08:37.993103+00:00,en,benzinga.com,benzinga.com,2023-09-28,"NKE,CCL, ATVI, MDGL, TSLA: Top 5 Trending Stocks Today - Tesla (NASDAQ:TSLA), Activision Blizzard (NASDAQ:ATVI), Madrigal Pharmaceuticals (NASDAQ:MDGL), Nike (NYSE:NKE)",https://www.benzinga.com/markets/equities/23/09/34990254/nike-carnival-activision-blizzard-madrigal-pharmaceuticals-tesla-why-these-5-stocks-are-on-inves
6466d644a6362db007a499345c88e285d36d655e071f3fc3bb262791bc459348,2024-02-19 07:47:43.666692+00:00,en,benzinga.com,benzinga.com,2023-10-12,Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),https://www.benzinga.com/pressreleases/23/10/g35229184/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4
b4fb58b82eea0ec89a1e5c36fa09dc273c2f4341603f1908f57e5d4d4a6ad3ed,2024-02-17 18:40:30.433739+00:00,en,benzinga.com,benzinga.com,2023-11-02,Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences,https://www.benzinga.com/pressreleases/23/11/g35575904/madrigal-pharmaceuticals-announces-participation-at-three-upcoming-investor-conferences
bebeccbe4b6d2b5ef2e7d9e4db553b777c3f5586c6eafb032f0dc31104237adb,2024-02-10 03:41:16.663439+00:00,en,investors.com,investors.com,2024-02-08,The Obesity Drug Update That Sent This Lilly Rival To A Record High,https://www.investors.com/news/technology/vktx-stock-charges-to-a-record-high-on-an-update-for-its-lilly-rivaling-obesity-treatment/?src=A00220&yptr=yahoo
5b630417b6cb6eea17edfef4f01ab6d7147bafe4d268cc6160b0ec0f47038d3d,2024-02-10 00:26:39.222431+00:00,en,benzinga.com,benzinga.com,2024-02-08,Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine,https://www.benzinga.com/pressreleases/24/02/g37005717/madrigal-pharmaceuticals-announces-publication-of-the-phase-3-maestro-nash-trial-of-resmetirom-in-
5164153f1ff6cd311834411a51163bec3332a80dedd12fb5b6483f27fdaa0fde,2024-01-14 00:20:04+00:00,en,benzinga.com,benzinga.com,2024-01-12,Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development,https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36616531/liver-disease-player-89bio-downgraded-analyst-sees-short-term-uncertainties-in-fatt
25153697a5c6a3bca8742d46b7055f6c598cc7b13e98d3cd417798a01e8c7d90,2024-01-05 01:31:02+00:00,en,benzinga.com,benzinga.com,2024-01-03,Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.benzinga.com/pressreleases/24/01/g36479545/madrigal-pharmaceuticals-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference
95ff03a54338756249aee81ff3a558b80232f9b9eacb2b23dca06d1caa9813bf,2023-12-17 02:51:05+00:00,en,upi.com,upi.com,2023-12-15,Weight-loss medications captured Americans' attention in 2023,https://www.upi.com/Health_News/2023/12/15/new-drug-approvals-2023-2024/6821702074748/
c32af0154e6f386ffc8df1f20b0bb3a6cb7f5da00c15ead7a22185737ce9ea30,2023-12-10 00:12:24+00:00,en,benzinga.com,benzinga.com,2023-12-07,Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009),https://www.benzinga.com/pressreleases/23/12/g36142897/aligos-therapeutics-presents-positive-clinical-data-at-hep-dart-2023-from-phase-1-studies-in-hbv-a
fb2e978248b72ec313b21807cbc5204eb993b285cd80fa2d8b98a67da9efc715,2023-11-23 00:22:23+00:00,en,benzinga.com,benzinga.com,2023-11-21,Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer,https://www.benzinga.com/pressreleases/23/11/g35892268/madrigal-pharmaceuticals-appoints-ronald-filippo-as-chief-information-officer
72c6f133af0d9af9ef472beef363cf665f4ba45c4d5fa30afee3856fff17ed1b,2023-11-17 00:24:06+00:00,en,benzinga.com,benzinga.com,2023-11-15,Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),https://www.benzinga.com/pressreleases/23/11/g35817219/madrigal-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4
7cb37a719760242ad57bd48a0aeef1aa3adee8ed7526a03160368f49adbdf748,2023-11-15 00:33:17+00:00,en,benzinga.com,benzinga.com,2023-11-13,Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease,https://www.benzinga.com/pressreleases/23/11/g35762066/hepion-pharmaceuticals-announces-major-reductions-in-liver-stiffness-with-rencofilstat-treatment-i
cee4efccd5d824f01c78688f03137736ffba7b677f2ccebe71f5d641e285ed5f,2023-11-12 00:12:03+00:00,en,benzinga.com,benzinga.com,2023-11-10,Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health,https://www.benzinga.com/pressreleases/23/11/g35723725/madrigal-pharmaceuticals-presents-new-data-from-the-phase-3-maestro-nash-trial-demonstrating-broad
8c645f732b2f427e7613191fcde4b471586965d6995923d8a416508f770f054b,2023-11-12 00:11:11+00:00,en,benzinga.com,benzinga.com,2023-11-10,Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer,https://www.benzinga.com/pressreleases/23/11/g35723195/madrigal-pharmaceuticals-appoints-carole-huntsman-as-chief-commercial-officer
